Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $38.50.

A number of equities research analysts have recently commented on ALGS shares. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Finally, Westpark Capital started coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective on the stock.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS opened at $5.59 on Friday. Aligos Therapeutics has a 1 year low of $4.80 and a 1 year high of $13.69. The firm’s 50 day moving average price is $5.68 and its 200 day moving average price is $7.19. The firm has a market cap of $34.60 million, a P/E ratio of -0.64 and a beta of 2.26.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The company had revenue of $2.83 million during the quarter, compared to the consensus estimate of $0.25 million. As a group, equities analysts predict that Aligos Therapeutics will post -7.47 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ALGS. Geode Capital Management LLC raised its stake in Aligos Therapeutics by 21.3% during the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after purchasing an additional 5,978 shares during the period. Rockefeller Capital Management L.P. boosted its holdings in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares during the last quarter. SummitTX Capital L.P. grew its stake in shares of Aligos Therapeutics by 6.7% during the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares during the period. Susquehanna International Group LLP purchased a new stake in shares of Aligos Therapeutics during the 3rd quarter valued at $99,000. Finally, LPL Financial LLC increased its holdings in shares of Aligos Therapeutics by 19.7% during the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after buying an additional 10,880 shares during the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.